⭐️ Update on longer outcomes with ribociclib (Kisqali) and abemaciclib (Verzenio) in hormone receptor positive/HER2 negative early stage breast cancer. ⭐️ These are CDK 4/6 inhibitors given in conjunction with endocrine therapy to reduce risk of recurrence. (CDK 4/6 inhibitors are standard of care in the treatment HR metastatic breast cancer as well). In early stage BC, abemaciclib is taken for 2 years and ribociclib for 3 years. In this video, I share with you recent updates (they are positive!
4:04
FacebookEleonora Teplinsky, MD
⭐️ Update on longer outcomes with ribociclib (Kisqali) and abemaciclib (Verzenio) in hormone receptor positive/HER2 negative early stage breast cancer. ⭐️ These are CDK 4/6
Eleonora Teplinsky, MD. . ⭐️ Update on longer outcomes with ribociclib (Kisqali) and abemaciclib (Verzenio) in hormone receptor positive/HER2 negative early stage breast cancer. ⭐️ These are CDK 4/6 inhibitors given in conjunction with endocrine therapy to reduce risk of recurrence. (CDK 4/6 inhibitors are standard of care in the ...
20.5K views7 months ago
Related Products
Ribociclib 200 Mg
Kisqali Ribociclib Tablets
Abemaciclib Palbociclib Ribociclib
#Ribociclib Uses
Ribociclib Kisqali Medication uses, side effects & Lowest cost
Ribociclib Kisqali Medication uses, side effects & Lowest cost
rumble.comJun 11, 2024
State Four Uses of Hydrogen: | Shaalaa.com
State Four Uses of Hydrogen: | Shaalaa.com
shaalaa.comSep 16, 2024
Top videos
Adding ribociclib to hormone therapy improves outcomes for patients with early breast cancer: Study
Adding ribociclib to hormone therapy improves outcomes for patients with early breast cancer: Study
theprint.in
Jun 4, 2023
In this video, I discuss ribociclib and abemaciclib in early stage HR /HER2- breast cancer. Both are CDK 4/6 inhibitors which interfere with the cell cycle and are used in combination with endocrine therapy to decrease the risk of recurrence. Ribociclib: 400 mg daily 21 days on/7 days off for 3 years At 5 years: absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib end
3:33
In this video, I discuss ribociclib and abemaciclib in early stage HR /HER2- breast cancer. Both are CDK 4/6 inhibitors which interfere with the cell cycle and are used in combination with endocrine therapy to decrease the risk of recurrence. Ribociclib: 400 mg daily 21 days on/7 days off for 3 years At 5 years: absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib end
FacebookEleonora Teplinsky, MD
13.6K views5 months ago
Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
ucla.edu
Jun 1, 2019
Ribociclib Side Effects
Kisqali (ribociclib) effets secondaires, interactions, utilisations et empreinte thérapeutique - Santé 2026
Kisqali (ribociclib) effets secondaires, interactions, utilisations et empreinte thérapeutique - Santé 2026
oldmedic.com
Sep 2, 2019
Let me know your symptoms/side effects of the ribociclib. Also how your feeling since taking it. #breastcancer #cancertreatments #lifeaftercancer #cancersurvivor #breastcancersurvivor
2:13
Let me know your symptoms/side effects of the ribociclib. Also how your feeling since taking it. #breastcancer #cancertreatments #lifeaftercancer #cancersurvivor #breastcancersurvivor
TikTokjadesjourney90
832 views2 months ago
Differentiating Between Abemaciclib and Ribociclib | OncLive
Differentiating Between Abemaciclib and Ribociclib | OncLive
onclive.com
3 months ago
Adding ribociclib to hormone therapy improves outcomes for patients with early breast cancer: Study
Adding ribociclib to hormone therapy improves outcomes for pa…
Jun 4, 2023
theprint.in
In this video, I discuss ribociclib and abemaciclib in early stage HR /HER2- breast cancer. Both are CDK 4/6 inhibitors which interfere with the cell cycle and are used in combination with endocrine therapy to decrease the risk of recurrence. Ribociclib: 400 mg daily 21 days on/7 days off for 3 years At 5 years: absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib end
3:33
In this video, I discuss ribociclib and abemaciclib in early stage HR /HE…
13.6K views5 months ago
FacebookEleonora Teplinsky, MD
Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
Adding ribociclib to hormone therapy extends lives of women wi…
Jun 1, 2019
ucla.edu
Ribociclib in Early Breast Cancer | NEJM
2:00
Ribociclib in Early Breast Cancer | NEJM
4K viewsMar 28, 2024
YouTubeNEJM Group
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
1:48
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- bre…
753 viewsMay 20, 2024
YouTubeVJOncology
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
2:44
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- bre…
3.8K viewsJun 4, 2019
YouTubeMDedge: news and insights for busy physicians
Drug found to reduce risk of breast cancer coming back
1:27
Drug found to reduce risk of breast cancer coming back
Jun 2, 2023
ABC7 ChicagoSony Salzman
1:51
NATALEE: ribociclib and NSAI in HR+/HER2- early breast cancer
741 viewsSep 16, 2024
YouTubeVJOncology
Recent Updates on the NATALEE Trial: Ribociclib ET in Early Breas…
Mar 1, 2025
vumedi.com
Ribociclib Kisqali Medication uses, side effects & Lowest cost
Jun 11, 2024
rumble.com
7:18
Kisqali (Ribociclib) for Breast Cancer: Uses, Side Effects, and W…
20.3K viewsJul 7, 2024
YouTubeYerbba – Breast Cancer
1:41
ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- e…
565 viewsFeb 28, 2024
YouTubeVJOncology
Differentiating Between Abemaciclib and Ribociclib | OncLive
3 months ago
onclive.com
6:37
Adjuvant Ribociclib in Early Stage HR+ Breast Cancer: Clinical Insights
1K views4 months ago
YouTubeOncUpdates: Latest Oncology Insights
12:58
The Science Behind Kisqali: Understanding how this Targeted …
2.6K viewsSep 21, 2023
YouTubeInevid
3:09
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Bre…
781 viewsJul 1, 2024
YouTubeOncLive
Rethinking Ribociclib: Is 400 mg Noninferior to 600 mg for Metastat…
7 months ago
medscape.com
1:35
Ribociclib plus letrozole is tied to longer progression-free survival t…
3.9K viewsMar 10, 2022
FacebookThe New England Journal of Medicine
4:48
FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast C…
1.9K viewsSep 18, 2024
YouTubeEleonora Teplinsky, MD
7:14
Ribociclib for HR+ Advanced Breast Cancer
2.3K viewsMar 2, 2017
YouTubeOncLive
0:59
Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer
1.3K viewsMar 13, 2017
YouTubeOncLive
10:15
MONALEESA-3 OS results: fulvestrant/ribociclib in postmeno…
1K viewsSep 29, 2019
YouTubeVJOncology
1:11
Using Ribociclib in the First-Line Setting
838 viewsMay 22, 2017
YouTubeOncLive
0:27
Toxicities Associated with Ribociclib From MONALEESA-3 Tr…
521 viewsOct 14, 2019
YouTubeOncLive
2:56
Ribociclib mejora la supervivencia del cáncer de mama HR1-positivo/…
1.6K viewsApr 10, 2024
YouTubeCONECTIMED
2:23
LEADER: ribociclib plus endocrine therapy reduces ctDNA in high-ris…
135 views5 months ago
YouTubeVJOncology
3:08
Adding ribociclib to endocrine therapy shows an improvement in …
760 viewsJul 3, 2023
YouTubeecancer
2:46
RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/…
2.5K viewsDec 12, 2022
YouTubeVJOncology
0:55
Novartis' New Breast Cancer Drug | Kisqali® | N18S | CNBC TV18
7K viewsSep 18, 2024
YouTubeCNBC-TV18
See more videos
Static thumbnail place holder